|  Help  |  About  |  Contact Us

Publication : High-protein diet accelerates diabetes and kidney disease in the BTBR<i>ob/ob</i> mouse.

First Author  Björnson Granqvist A Year  2020
Journal  Am J Physiol Renal Physiol Volume  318
Issue  3 Pages  F763-F771
PubMed ID  31961715 Mgi Jnum  J:302634
Mgi Id  MGI:6509298 Doi  10.1152/ajprenal.00484.2019
Citation  Bjornson Granqvist A, et al. (2020) High-protein diet accelerates diabetes and kidney disease in the BTBRob/ob mouse. Am J Physiol Renal Physiol 318(3):F763-F771
abstractText  There is a need for improved animal models that better translate to human kidney disease to predict outcome of pharmacological effects in the patient. The diabetic BTBRob/ob mouse model mimics key features of early diabetic nephropathy in humans, but with chronic injury limited to glomeruli. To explore if we could induce an accelerated and more advanced disease phenotype that closer translates to human disease, we challenged BTBRob/ob mice with a high-protein diet (HPD; 30%) and followed the progression of metabolic and renal changes up to 20 wk of age. Animals on the HPD showed enhanced metabolic derangements, evidenced by further increased levels of glucose, HbA1C, cholesterol, and alanine aminotransferase. The urinary albumin-to-creatinine ratio was markedly increased with a 53-fold change compared with lean controls, whereas BTBRob/ob mice on the standard diet only presented an 8-fold change. HPD resulted in more advanced mesangial expansion already at 14 wk of age compared with BTBRob/ob mice on the standard diet and also aggravated glomerular pathology as well as interstitial fibrosis. Gene expression analysis revealed that HPD triggered expression of markers of fibrosis and inflammation in the kidney and increased oxidative stress markers in urine. This study showed that HPD significantly aggravated renal injury in BTBRob/ob mice by further advancing albuminuria, glomerular, and tubulointerstitial pathology by 20 wk of age. This mouse model offers closer translation to humans and enables exploration of new end points for pharmacological efficacy studies that also holds promise to shorten study length.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

4 Bio Entities

0 Expression